FDA Removes Tirzepatide from Drug Shortage List

The FDA has removed Eli Lilly's GLP-1 medications, Mounjaro and Zepbound, from its shortage list, effectively ending the ability of compounding pharmacies to sell cheaper, compounded versions. This decision has prompted a lawsuit from the Outsourcing Facilities Association, which argues that the FDA's action is arbitrary and deprives patients of necessary treatment while raising drug prices. The FDA asserted that Eli Lilly's manufacturing capacity is sufficient to meet demand, despite ongoing localized supply disruptions. Analysts suggest the ruling strengthens Lilly's position against competitors selling compounded versions. While compounded medications for Mounjaro and Zepbound are now restricted, Novo Nordisk's Ozempic and Wegovy remain on the shortage list, allowing those versions to continue being sold. The outcome of the lawsuit could have significant implications for the compounding pharmacy industry and patient access to affordable treatments.